Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FluMist Refrigerator-Stable Formula On Track For 2007/2008 After FDA “Complete Response”

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA seeks clarification on data already submitted to support approval of the influenza vaccine sBLA.

You may also be interested in...



MedImmune Puts FluMist In FDA's Fridge

The company is positioning the refrigerator-stable version for launch next year with labeling covering children as young as one.

MedImmune Puts FluMist In FDA's Fridge

The company is positioning the refrigerator-stable version for launch next year with labeling covering children as young as one.

Refrigerator-Stable FluMist Submitted For Young Children

MedImmune submitted a supplemental BLA seeking use of refrigerator-stable intranasal flu vaccine FluMist to inoculate children ages 12 months to 59 months, the company announced July 31

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel